--- title: "Tropisetron: Dosing & Vendor Prices — BodyHackGuide" description: "Tropisetron: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Tropisetron" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Tropisetron", "description": "Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug. Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031). Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693). Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724). Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational.", "url": "https://www.bodyhackguide.co/compound/tropisetron", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "89.99", "highPrice": "89.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "89.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/tropiestron/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Tropisetron", "description": "Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug. Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031). Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693). Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724). Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational.", "lastReviewed": "2026-09-07T04:48:26.791Z", "url": "https://www.bodyhackguide.co/compound/tropisetron", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Tropisetron", "alternateName": [ "ICS 205-930", "SDZ ICS 930", "Navoban", "Novaban", "Tropisetron hydrochloride", "Tropiestron (market misspelling)" ], "description": "Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug. Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031). Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693). Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724). Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational.", "activeIngredient": "Tropisetron", "administrationRoute": "Oral, Intravenous injection", "mechanismOfAction": "Tropisetron is a potent and selective serotonin 5-HT3 receptor antagonist, the property behind its antiemetic license, blocking 5-HT3 receptors on peripheral neurones involved in the emetic reflex with possible additional action at 5-HT3 receptors in the area postrema (PMID: 8363993). It is also a partial agonist at the alpha7 nicotinic acetylcholine receptor: oocyte electrophysiology showed the tropane portion of the molecule carries the alpha7 agonist activity while the indole portion drives potency and selectivity (PMID: 15781147), and positron emission tomography with the alpha7 radioligand CHIBA-1001 showed a single oral dose reduced radioligand distribution volume in the human brain while ondansetron did not (PMID: 23430308). A screening study also identified binding to the ectodomain of amyloid precursor protein (PMID: 24389031). Clearance depends heavily on CYP2D6 (PMID: 11736884).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Tropisetron used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug. Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031). Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693). Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724). Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational." } }, { "@type": "Question", "name": "What forms does Tropisetron come in?", "acceptedAnswer": { "@type": "Answer", "text": "Tropisetron is available in capsule form." } }, { "@type": "Question", "name": "How much does Tropisetron cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $89.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Tropisetron vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Ftropisetron) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Tropisetron [Where to buy Tropisetron](/buy/tropisetron) [Tropisetron coupon codes](/coupons/tropisetron) [Tropisetron protocol](/protocol/tropisetron) [Alternatives to Tropisetron](/alternatives-to/tropisetron) [Tropisetron side effects](/side-effects/tropisetron) 1. [Home](/) 3. [Compounds](/compare) 5. Tropisetron ![Tropisetron molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Tropisetron Pharmaceutical Approved (Japan) Download PDF Also known as: ICS 205-930, SDZ ICS 930, Navoban, Novaban, Tropisetron hydrochloride, Tropiestron (market misspelling) Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Half-Life: About 5.7 h after a single 5 mg oral capsule and 5.6 h after 2 mg intravenously in 18 healthy volunteers; oral bioavailability averaged 0.60 with a range of 0.27 to 0.99 and was inversely related to CYP2D6 activity (PMID: 11736884) Route: Oral, Intravenous injection MW: 284.35 g/mol (free base) CAS: 89565-68-4 (free base); 105826-92-4 (hydrochloride) Last reviewed: Sep 7, 2026 [ Pharmaceutical Category ](/wiki#cat-pharmaceutical) Approved (Japan) Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $89.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/tropiestron/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Tropisetron is a potent and selective serotonin 5-HT3 receptor antagonist, the property behind its antiemetic license, blocking 5-HT3 receptors on peripheral neurones involved in the emetic reflex with possible additional action at 5-HT3 receptors in the area postrema (PMID: 8363… Half-Life About 5.7 h after a single 5 mg oral capsule and 5.6 h after 2 mg intravenously in 18 healthy volunteers; oral bioavailability averaged 0.60 with a range of 0.27 to 0.99 and was inversely related to CYP2D6 activity (PMID: 11736884) Routes Oral Intravenous injection Potential Benefits Improved cognition and P50 auditory gating in 40 non-smoking patients with schizophrenia in a randomized double-blind 10-day study (PMID: 22952075) Improved P50 gating and sustained visual attention in a randomized placebo-controlled 8-week study in 40 patients with schizophrenia (PMID: 20573264) Improved primary negative symptoms as an add-on to risperidone in a randomized placebo-controlled 8-week study in 40 patients with chronic schizophrenia (PMID: 23515583) Larger fall in pain scores than placebo in a randomized double-blind multicenter trial in 21 women with fibromyalgia, significant on the secondary body diagram score only (PMID: 15370724) Improved memory and the sAPPalpha to amyloid-beta ratio in J20 transgenic mice, with greater effect than memantine or donepezil at comparable doses (PMID: 24389031) Reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma, through alpha7 nicotinic receptors (PMID: 23440693) ### Overview Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug. Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031). Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693). Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724). Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational. ### Potential Research Fields 5-HT3 receptor antagonists Alpha7 nicotinic receptor pharmacology Antiemetics Schizophrenia cognition Fibromyalgia ## Chemical Information IUPAC Name Not yet available CAS Number 89565-68-4 (free base); 105826-92-4 (hydrochloride) Molecular Formula C17H20N2O2 Molecular Mass 284.35 g/mol (free base) ![Tropisetron molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/656665/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/656665) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Sourced and mechanism-based: metabolism depends on CYP2D6, so ultrarapid metabolisers get lower exposure and reduced antiemetic effect while poor metabolisers get higher exposure and more adverse effects (PMID: 12065557, PMID: 11736884), the basis of the Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 41979467). Constipation and other gastrointestinal effects make pre-existing bowel obstruction or severe constipation a mechanism-based concern (PMID: 8363993). Use outside a licensed antiemetic indication is investigational and unsupervised use carries no evidence base. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $89.99 Best $/mg — Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Tropisetron capsules (60) capsule 60 capsules ● In Stock $89.99 BEST — — [Buy](https://disguisedalpha.com/product/tropiestron/?coupon=reddit) Get Tropisetron Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $89.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Tropisetron. [Sign in](/auth) Current low $89.99 as of Sep 7, 2026 7-day low $89.99 30-day low $89.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Tropisetron [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $89.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### Albuterol (salbutamol) Pharmaceutical FDA Approved Albuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide. t½ Mean terminal half-life 3.8 hours after intravenous administration in 16 healthy adult men, with absolute oral bioavailability of 44 percent and plasma peaks one to three hours after oral administration (PMID: 3653233) Preclinical View Profile ](/compound/albuterol)[ ### Clascoterone Pharmaceutical Preclinical Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S. 1188 studies View Profile ](/compound/clascoterone)[ ### Finasteride Pharmaceutical Preclinical Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss). Preclinical View Profile ](/compound/finasteride)[ ### Meldonium Pharmaceutical Approved (Latvia) Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries. t½ Not a single simple value: in 32 healthy athlete volunteers taking oral meldonium for three weeks, plasma took several days to reach steady state and urinary elimination continued for several months after the last dose, because tissue clearance depends on slow diffusion rather than transport (PMID: 30328291) Preclinical View Profile ](/compound/meldonium)[ ### Mirabegron Pharmaceutical FDA Approved Mirabegron is an approved prescription drug, not a research chemical. t½ Terminal half-life about 32 hours in one phase 1 multiple-dose study and about 60 hours in a second, with plasma peaks at three to five hours and steady state within seven days in healthy young and elderly adults (PMID: 23063375) Preclinical View Profile ](/compound/mirabegron) [ View Full Dosage Guide → Protocols, calculator & safety for Tropisetron ](/guides/dosage/tropisetron) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $89.99 [Buy Now](https://disguisedalpha.com/product/tropiestron/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life About 5.7 h after a single 5 mg oral capsule and 5.6 h after 2 mg intravenously in 18 healthy volunteers; oral bioavailability averaged 0.60 with a range of 0.27 to 0.99 and was inversely related to CYP2D6 activity (PMID: 11736884) Molecular Weight 284.35 g/mol (free base) Administration Oral, Intravenous injection CAS Number 89565-68-4 (free base); 105826-92-4 (hydrochloride) Trial Phase Approved (Japan) 0 [Full Dosage Guide](/guides/dosage/tropisetron)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Tropisetron used for in research? Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug. Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031). Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693). Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724). Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational. What forms does Tropisetron come in? Tropisetron is available in capsule form. How much does Tropisetron cost? Prices start at $89.99 across 1 verified vendor. How do I compare Tropisetron vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### Albuterol (salbutamol) Pharmaceutical FDA Approved Albuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide. t½ Mean terminal half-life 3.8 hours after intravenous administration in 16 healthy adult men, with absolute oral bioavailability of 44 percent and plasma peaks one to three hours after oral administration (PMID: 3653233) Preclinical View Profile ](/compound/albuterol)[ ### Clascoterone Pharmaceutical Preclinical Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S. 1188 studies View Profile ](/compound/clascoterone)[ ### Finasteride Pharmaceutical Preclinical Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss). Preclinical View Profile ](/compound/finasteride)[ ### Meldonium Pharmaceutical Approved (Latvia) Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries. t½ Not a single simple value: in 32 healthy athlete volunteers taking oral meldonium for three weeks, plasma took several days to reach steady state and urinary elimination continued for several months after the last dose, because tissue clearance depends on slow diffusion rather than transport (PMID: 30328291) Preclinical View Profile ](/compound/meldonium)[ ### Mirabegron Pharmaceutical FDA Approved Mirabegron is an approved prescription drug, not a research chemical. t½ Terminal half-life about 32 hours in one phase 1 multiple-dose study and about 60 hours in a second, with plasma peaks at three to five hours and steady state within seven days in healthy young and elderly adults (PMID: 23063375) Preclinical View Profile ](/compound/mirabegron) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-tropisetron) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋